Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management.
Ansell SM.
Am J Hematol. 2024 Dec;99(12):2367-2378. doi: 10.1002/ajh.27470. Epub 2024 Sep 6.
Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A Report from the CIBMTR.
Spellman SR, Xu K, Oloyede T, Ahn KW, Akhtar O, Bolon YT, Broglie L, Bloomquist J, Bupp C, Chen M, Devine SM, El-Jurdi N, Hamadani M, Hengen M, Huppler AH, Jaglowski S, Kuxhausen M, Lee SJ, Moskop A, Page KM, Pasquini MC, Perez W, Phelan R, Rizzo D, Saber W, Stefanski HE, Steinert P, Tuschl E, Visotcky A, Vogel R, Auletta JJ, Shaw BE, Allbee-Johnson M.
Transplant Cell Ther. 2025 Aug;31(8):505-532. doi: 10.1016/j.jtct.2025.05.014. Epub 2025 May 19.
Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: myeloablative, non-myeloablative, and beyond.
Hwang YY, Mohty M, Chim CS.
Hematology. 2015 Mar;20(2):61-71. doi: 10.1179/1607845414Y.0000000175. Epub 2014 Jul 3.
Allogeneic hematopoietic stem cell transplantation after immunosuppressive but non-myeloablative conditioning: "miniallografts" are no small matter.
Martino R, Sierra J.
Haematologica. 1998 Oct;83(10):865-7.
Non-myeloablative transplantation.
Maloney DG, Sandmaier BM, Mackinnon S, Shizuru JA.
Hematology Am Soc Hematol Educ Program. 2002:392-421. doi: 10.1182/asheducation-2002.1.392.
Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis. A Population-Based Study from Eastern Denmark.
Holmström MO, Minculescu L, Nørgaard K, Kornblit BT, Schjødt I, Nygaard M, Andersen NS, Sengeløv H, Bruunsgaard H, Petersen SL, Andersen MK, Friis LS.
Transplant Cell Ther. 2025 Jun;31(6):365.e1-365.e13. doi: 10.1016/j.jtct.2025.03.006. Epub 2025 Mar 17.
Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas.
Othman T, Moskoff BN, Esteghamat N, Hoeg RT, Rosenberg AS, Jonas BA, Abedi M, Richman C, Tuscano JM.
Leuk Lymphoma. 2022 Jan;63(1):231-234. doi: 10.1080/10428194.2021.1975190. Epub 2021 Sep 6.
Allogeneic Hematopoietic Cell Transplantation with Non-Myeloablative Conditioning and Post-Transplant Cyclophosphamide Prophylaxis in Patients with Reduced Systolic Function.
LeMaistre FI, Tsai HL, Varadhan R, Al-Talib T, Jones R, Ambinder A.
Transplant Cell Ther. 2024 Feb;30(2):208.e1-208.e7. doi: 10.1016/j.jtct.2023.10.011. Epub 2023 Oct 12.
Functional immune reconstitution after allogeneic hematopoietic stem cell transplantation in myeloablative and non-myeloablative conditioned patients.
Brooks PT, Minculescu L, Svanberg Teglgaard R, Hartling HJ, Salado-Jimena JA, Friis LS, Kornblit B, Schjødt I, Petersen SL, Andersen NS, Nielsen SD, Lundgren J, Marquart HV, Gjaerde LK, Sengeløv H, Ostrowski SR.
Sci Rep. 2025 Jul 1;15(1):21029. doi: 10.1038/s41598-025-06718-y.
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades.
Cooper JP, Storer BE, Granot N, Gyurkocza B, Sorror ML, Chauncey TR, Shizuru J, Franke GN, Maris MB, Boyer M, Bruno B, Sahebi F, Langston AA, Hari P, Agura ED, Lykke Petersen S, Maziarz RT, Bethge W, Asch J, Gutman JA, Olesen G, Yeager AM, Hübel K, Hogan WJ, Maloney DG, Mielcarek M, Martin PJ, Flowers MED, Georges GE, Woolfrey AE, Deeg JH, Scott BL, McDonald GB, Storb R, Sandmaier BM.
Haematologica. 2021 Jun 1;106(6):1599-1607. doi: 10.3324/haematol.2020.248187.
